The loss of midbrain dopamine in Parkinson's disease is accompanied by a matching loss in the dopamine transporter and a rise in the Dl and D2 receptor densities. This is found in the brain putamen and caudate tissues from unmedicated patients, and may account for the good early clinical response to L-dopa. Longterm L-dopa treatment reverts the receptor densities toward normal levels. Positron emission tomography (PET) data and in vitro data generally concur. In schizophrenia the density of the dopamine transporter as well as that of the Dl dopamine receptor is normal. The D2 receptor density, however, is consistently elevated in postmortem brain putamen and caudate nucleus, even in tissues from neuroleptic-free or drugnaive patients. Three sets of PET and single photon emission computed tomography (SPECT) data support the postmortem findings. Early evidence indicating abnormal D2 structure as well as a reduced link between Dl and D2 warrant a detailed study of the genes for these two receptors in schizophrenia. 
by 60-86% of age-matched control tissues (1), the loss of dopamine in the nerve terminals in the striaturn is even greater, amounting to a 90-99% loss in the putamen (2, 7-9) and a 58-95% loss in the caudate nucleus (2, 7-9). Until now it has been puzzling that the dopamine transporter, which is located on the nerve terminals, falls by only 22-60%, whereas the dopamine content drops by more than 90%. For example, Fig. 1 
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The FASEB Journal by 1 tM mazindol) were virtually absent in the Parkinson putamen after the tissue had been partly purified by using a wheat-germ agglutinin column. An example is shown in Fig. 2 Vol. The density of D2 receptors is consistently elevated in postmortem striatal tissues (Fig. 4, bottom (40) reported that postmortem D2 densities were not elevated in tissues from patients who had not received neuroleptics for 10 days or more before death, their findings are not supported by others (33, 36, 48, 49) , as shown in Fig. 4 .
The long-term administration of neuroleptics to patients increases the density of D2 dopamine receptors in postmortem human tissues by only 25%. For example, the top panel of Fig. 5 Fig. 5 ).
In schizophrenia, however, at least half of the brain striata revealed D2 densities between 22 and 40 pmol/g (Fig. 5, second 
